Valneva SE (INRLF)
USD 1.98
(0.0%)
USD 1.98
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 469.39 Million EUR | -24.46% |
| 2022 | 621.34 Million EUR | -23.98% |
| 2021 | 817.35 Million EUR | 81.97% |
| 2020 | 449.16 Million EUR | 69.67% |
| 2019 | 264.72 Million EUR | 15.14% |
| 2018 | 229.9 Million EUR | 21.42% |
| 2017 | 189.34 Million EUR | -8.48% |
| 2016 | 206.88 Million EUR | -24.82% |
| 2015 | 275.18 Million EUR | 20.95% |
| 2014 | 227.51 Million EUR | -10.56% |
| 2013 | 254.39 Million EUR | 374.02% |
| 2012 | 53.66 Million EUR | -26.57% |
| 2011 | 73.08 Million EUR | -8.07% |
| 2010 | 79.49 Million EUR | 73.0% |
| 2009 | 45.95 Million EUR | 11.04% |
| 2008 | 41.38 Million EUR | 4.55% |
| 2007 | 39.58 Million EUR | 165.27% |
| 2006 | 14.92 Million EUR | 2.2% |
| 2005 | 14.6 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 502.82 Million EUR | 7.12% |
| 2024 Q2 | 466.56 Million EUR | -7.21% |
| 2023 Q2 | 542.57 Million EUR | -8.04% |
| 2023 Q4 | 469.39 Million EUR | -9.83% |
| 2023 FY | 469.39 Million EUR | -24.46% |
| 2023 Q3 | 520.53 Million EUR | -4.06% |
| 2023 Q1 | 590 Million EUR | -5.04% |
| 2022 Q2 | 725.1 Million EUR | -6.76% |
| 2022 Q1 | 777.71 Million EUR | -4.85% |
| 2022 Q4 | 621.34 Million EUR | -10.99% |
| 2022 FY | 621.34 Million EUR | -23.98% |
| 2022 Q3 | 698.08 Million EUR | -3.73% |
| 2021 Q2 | 745.1 Million EUR | 29.78% |
| 2021 FY | 817.35 Million EUR | 81.97% |
| 2021 Q1 | 574.11 Million EUR | 27.82% |
| 2021 Q4 | 817.35 Million EUR | 0.0% |
| 2020 Q3 | 450.18 Million EUR | 15.63% |
| 2020 Q4 | 449.16 Million EUR | -0.23% |
| 2020 Q2 | 389.34 Million EUR | 40.78% |
| 2020 Q1 | 276.57 Million EUR | 4.48% |
| 2020 FY | 449.16 Million EUR | 69.67% |
| 2019 FY | 264.72 Million EUR | 15.14% |
| 2019 Q1 | 243.74 Million EUR | 6.02% |
| 2019 Q4 | 264.72 Million EUR | 5.62% |
| 2019 Q3 | 250.64 Million EUR | 0.6% |
| 2019 Q2 | 249.14 Million EUR | 2.22% |
| 2018 FY | 229.9 Million EUR | 21.42% |
| 2018 Q1 | 186.5 Million EUR | -1.5% |
| 2018 Q4 | 229.9 Million EUR | 31.12% |
| 2018 Q3 | 175.33 Million EUR | -3.38% |
| 2018 Q2 | 181.47 Million EUR | -2.7% |
| 2017 Q4 | 189.34 Million EUR | -1.24% |
| 2017 FY | 189.34 Million EUR | -8.48% |
| 2017 Q2 | 198.2 Million EUR | -0.19% |
| 2017 Q1 | 198.56 Million EUR | -4.02% |
| 2017 Q3 | 191.73 Million EUR | -3.26% |
| 2016 Q4 | 206.88 Million EUR | 1.93% |
| 2016 FY | 206.88 Million EUR | -24.82% |
| 2016 Q3 | 202.96 Million EUR | -3.25% |
| 2016 Q2 | 209.78 Million EUR | -15.19% |
| 2016 Q1 | 247.34 Million EUR | -10.12% |
| 2015 Q4 | 275.18 Million EUR | 0.32% |
| 2015 Q1 | 290.63 Million EUR | 27.74% |
| 2015 FY | 275.18 Million EUR | 20.95% |
| 2015 Q2 | 283.08 Million EUR | -2.6% |
| 2015 Q3 | 274.31 Million EUR | -3.1% |
| 2014 Q4 | 227.51 Million EUR | -5.36% |
| 2014 FY | 227.51 Million EUR | -10.56% |
| 2014 Q3 | 240.39 Million EUR | -1.23% |
| 2014 Q2 | 243.38 Million EUR | 0.87% |
| 2014 Q1 | 241.29 Million EUR | -5.15% |
| 2013 Q4 | 254.39 Million EUR | 5.16% |
| 2013 FY | 254.39 Million EUR | 374.02% |
| 2013 Q3 | 241.9 Million EUR | -1.37% |
| 2013 Q2 | 245.27 Million EUR | 0.0% |
| 2013 Q1 | - EUR | -100.0% |
| 2012 FY | 53.66 Million EUR | -26.57% |
| 2012 Q2 | 60.44 Million EUR | 0.0% |
| 2012 Q4 | 53.66 Million EUR | 0.0% |
| 2011 FY | 73.08 Million EUR | -8.07% |
| 2011 Q2 | 79.35 Million EUR | 0.0% |
| 2011 Q4 | 73.08 Million EUR | 0.0% |
| 2010 FY | 79.49 Million EUR | 73.0% |
| 2010 Q2 | 54.8 Million EUR | 0.0% |
| 2010 Q4 | 79.49 Million EUR | 0.0% |
| 2009 Q4 | 45.95 Million EUR | 0.0% |
| 2009 FY | 45.95 Million EUR | 11.04% |
| 2008 FY | 41.38 Million EUR | 4.55% |
| 2007 FY | 39.58 Million EUR | 165.27% |
| 2006 FY | 14.92 Million EUR | 2.2% |
| 2005 FY | 14.6 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -1108.307% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -6401.475% |
| SQZ Biotechnologies Company | 107.18 Million USD | -337.918% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -4347.518% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -260.486% |
| Mesoblast Limited | 667.9 Million USD | 29.721% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -648543.681% |
| Genus plc | 1.02 Billion USD | 54.379% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -34455.892% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -93958.981% |
| Marizyme, Inc. | 22.01 Million USD | -2032.134% |
| ContraFect Corporation | 20.67 Million USD | -2169.892% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -74762.998% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -120143.822% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -122720.316% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -32677.969% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -11221.479% |
| MultiCell Technologies, Inc. | 126.22 USD | -371883119.775% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -49851.739% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -265.256% |
| EV Biologics, Inc. | 431.71 Thousand USD | -108627.306% |
| Q BioMed Inc. | 3.51 Million USD | -13251.976% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -1234.293% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -60808.928% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -179552.629% |
| Biomind Labs Inc. | 73.81 Thousand USD | -635767.46% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | -1.412% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -1463.857% |
| Skye Bioscience, Inc. | 11.94 Million USD | -3831.113% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -14068.104% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -16991.542% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -23870.669% |
| IMV Inc. | 31.33 Million USD | -1398.035% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -68176.445% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -17931.335% |
| GB Sciences, Inc. | 103.44 Thousand USD | -453672.162% |
| Alpha Cognition Inc. | 2.45 Million USD | -19041.862% |
| HST Global, Inc. | 1526.00 USD | -30759467.497% |
| CSL Limited | 38.02 Billion USD | 98.765% |
| Halberd Corporation | 10.13 Thousand USD | -4633114.885% |
| Enzolytics Inc. | 361.7 Million USD | -29.771% |
| Resverlogix Corp. | 8.11 Million USD | -5684.239% |
| Affymax, Inc. | 7.44 Million USD | -6206.476% |
| SYBLEU INC | 330.46 Thousand USD | -141938.261% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -24895.793% |
| argenx SE | 4.54 Billion USD | 89.667% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -1579.756% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -884.007% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -2060349.497% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -5145.087% |
| AVAX Technologies, Inc. | 7.37 Million USD | -6262.763% |
| Zenith Capital Corp. | 7410.00 USD | -6334461.404% |
| Genscript Biotech Corporation | 3.38 Billion USD | 86.139% |
| Ember Therapeutics, Inc. | 184.00 USD | -255103704.348% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -145761.482% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -179492.828% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -5.172% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -32297.644% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -15416.617% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -790.668% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -50483.053% |
| BioStem Technologies, Inc. | 14.56 Million USD | -3123.775% |
| ONE Bio Corp. | 70.08 Million USD | -569.74% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -822037.177% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -20319856.71% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -47410.797% |
| Agentix Corp. | 261.39 Thousand USD | -179473.591% |
| LadRx Corporation | 2.3 Million USD | -20238.605% |
| Cell Source, Inc. | 195.17 Thousand USD | -240402.431% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -97576.446% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -132639.942% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -132639.942% |
| NovAccess Global Inc. | 62.24 Thousand USD | -753965.994% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -73281.786% |
| Itoco Inc. | 1.4 Million USD | -33426.204% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -490602.196% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -442721.698% |
| Kadimastem Ltd | 2.3 Million USD | -20272.166% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -614656.267% |
| CytoDyn Inc. | 11.13 Million USD | -4115.077% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -328209.739% |
| Mobile Lads Corp. | 52.00 USD | -902674900.0% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -2625129.306% |
| Qrons Inc. | 420.00 USD | -111759661.905% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -121670.769% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -84916.12% |
| Rebus Holdings, Inc. | 5000.00 USD | -9387720.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -114547.234% |
| International Stem Cell Corporation | 5.39 Million USD | -8608.553% |
| Bioxytran, Inc. | 137.63 Thousand USD | -340933.0% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -3028.892% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -2731.238% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -594065.823% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -54185.126% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -6144.393% |
| Neutra Corp. | 2851.00 USD | -16463982.778% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1348.469% |
| PureTech Health plc | 693.97 Million USD | 32.362% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -5715.708% |
| IXICO plc | 15.84 Million USD | -2862.597% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -5567.604% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -354.29% |
| CSL Limited | 38.02 Billion USD | 98.765% |
| Cellectis S.A. | 333.99 Million USD | -40.538% |